Mirae Asset Global Investments Co., Ltd. Bluebird Bio, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

  • $22.5 Billion
  • Q3 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,885 shares of BLUE stock, worth $63,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,885
Previous 5,683 21.15%
Holding current value
$63,204
Previous $5,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024
BUY
$0.47 - $1.35 $564 - $1,622
1,202 Added 21.15%
6,885 $3,000
Q2 2024

Jul 30, 2024
SELL
$0.85 - $1.26 $271,513 - $402,479
-319,428 Reduced 98.25%
5,683 $5,000
Q1 2024

May 01, 2024
BUY
$0.91 - $1.75 $82,026 - $157,743
90,139 Added 38.36%
325,111 $416,000
Q4 2023

Jan 24, 2024
SELL
$1.32 - $4.83 $443,467 - $1.62 Million
-335,960 Reduced 58.84%
234,972 $324,000
Q3 2023

Oct 26, 2023
BUY
$3.02 - $4.05 $91,992 - $123,367
30,461 Added 5.64%
570,932 $1.74 Million
Q2 2023

Aug 10, 2023
BUY
$2.79 - $5.03 $431,029 - $777,089
154,491 Added 40.03%
540,471 $1.78 Million
Q1 2023

May 04, 2023
BUY
$3.14 - $8.22 $202,768 - $530,814
64,576 Added 20.09%
385,980 $1.23 Million
Q4 2022

Feb 09, 2023
SELL
$5.77 - $8.49 $224,770 - $330,727
-38,955 Reduced 10.81%
321,404 $2.22 Million
Q3 2022

Nov 10, 2022
BUY
$3.75 - $7.39 $176,820 - $348,453
47,152 Added 15.05%
360,359 $2.28 Million
Q2 2022

Jul 26, 2022
BUY
$2.94 - $5.23 $287,611 - $511,635
97,827 Added 45.42%
313,207 $1.3 Million
Q1 2022

May 10, 2022
SELL
$4.07 - $10.6 $187,753 - $488,988
-46,131 Reduced 17.64%
215,380 $1.04 Million
Q4 2021

Feb 08, 2022
BUY
$8.96 - $16.31 $443,878 - $807,997
49,540 Added 23.37%
261,511 $2.61 Million
Q3 2021

Nov 15, 2021
BUY
$11.24 - $21.0 $441,113 - $824,145
39,245 Added 22.72%
211,971 $4.05 Million
Q2 2021

Aug 11, 2021
BUY
$18.04 - $22.09 $46,831 - $57,345
2,596 Added 1.53%
172,726 $5.52 Million
Q1 2021

May 13, 2021
BUY
$16.59 - $33.89 $902,313 - $1.84 Million
54,389 Added 46.99%
170,130 $5.13 Million
Q4 2020

Feb 10, 2021
BUY
$27.5 - $37.92 $1.22 Million - $1.68 Million
44,422 Added 62.29%
115,741 $5.01 Million
Q3 2020

Nov 12, 2020
BUY
$34.44 - $43.75 $751,859 - $955,106
21,831 Added 44.11%
71,319 $3.88 Million
Q2 2020

Aug 11, 2020
BUY
$27.12 - $45.97 $963,953 - $1.63 Million
35,544 Added 254.91%
49,488 $3.02 Million
Q1 2020

May 12, 2020
BUY
$26.16 - $63.5 $99,905 - $242,506
3,819 Added 37.72%
13,944 $640,000
Q4 2019

Feb 12, 2020
BUY
$46.96 - $61.67 $199,345 - $261,789
4,245 Added 72.19%
10,125 $888,000
Q3 2019

Nov 12, 2019
BUY
$59.47 - $93.1 $196,369 - $307,416
3,302 Added 128.08%
5,880 $539,000
Q2 2019

Aug 13, 2019
BUY
$75.84 - $105.21 $98,212 - $136,246
1,295 Added 100.94%
2,578 $328,000
Q1 2019

May 13, 2019
BUY
$64.44 - $104.11 $82,676 - $133,573
1,283 New
1,283 $202,000
Q4 2018

Feb 11, 2019
SELL
$59.1 - $93.26 $336,988 - $531,768
-5,702 Closed
0 $0
Q3 2018

Nov 13, 2018
BUY
$88.86 - $117.49 $186,072 - $246,024
2,094 Added 58.04%
5,702 $832,000
Q2 2018

Aug 14, 2018
BUY
$99.64 - $127.59 $2,291 - $2,934
23 Added 0.64%
3,608 $566,000
Q1 2018

May 10, 2018
SELL
$105.8 - $150.94 $145,051 - $206,938
-1,371 Reduced 27.66%
3,585 $612,000
Q4 2017

Feb 12, 2018
SELL
$81.25 - $130.7 $61,425 - $98,809
-756 Reduced 13.24%
4,956 $883,000
Q3 2017

Nov 08, 2017
BUY
$57.74 - $91.42 $3,984 - $6,307
69 Added 1.22%
5,712 $785,000
Q2 2017

Aug 14, 2017
BUY
N/A
5,643
5,643 $593,000

Others Institutions Holding BLUE

# of Institutions
150
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $708M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email